## Jannick Prentoe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8236192/publications.pdf Version: 2024-02-01



IANNICK PRENTOE

#	Article	IF	CITATIONS
1	Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. Journal of Hepatology, 2022, 76, 1051-1061.	1.8	11
2	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines, 2021, 9, 291.	2.1	11
3	Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity, 2021, 54, 781-796.e4.	6.6	23
4	In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. PLoS Pathogens, 2021, 17, e1009720.	2.1	3
5	Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS ONE, 2021, 16, e0255336.	1.1	2
6	Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1. Current Opinion in Virology, 2021, 50, 69-75.	2.6	8
7	An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Science Advances, 2020, 6, eabb5642.	4.7	26
8	Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Science Advances, 2020, 6, eabb5938.	4.7	29
9	Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines, 2020, 8, 294.	2.1	14
10	Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro. Proceedings (mdpi), 2020, 50, .	0.2	0
11	Hepatitis C Virus–Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. Journal of Infectious Diseases, 2019, 219, 68-79.	1.9	15
12	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathogens, 2019, 15, e1007772.	2.1	45
13	Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10039-10047.	3.3	44
14	Genetic and structural insights into broad neutralization of hepatitis C virus by human V <sub>H</sub> 1-69 antibodies. Science Advances, 2019, 5, eaav1882.	4.7	77
15	Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. Journal of Virology, 2019, 93, .	1.5	21
16	In Vitro Neutralization Assay Using Cultured Hepatitis C Virus. Methods in Molecular Biology, 2019, 1911, 433-439.	0.4	7
17	Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. Journal of Virology, 2018, 92, .	1.5	12
18	High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Scientific Reports, 2018, 8, 17505.	1.6	10

JANNICK PRENTOE

#	Article	IF	CITATIONS
19	Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Frontiers in Immunology, 2018, 9, 2146.	2.2	45
20	Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. PLoS Pathogens, 2017, 13, e1006214.	2.1	23
21	Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. Hepatology, 2016, 64, 1881-1892.	3.6	69
22	HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. Gut, 2016, 65, 1988-1997.	6.1	38
23	Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. Journal of Virology, 2015, 89, 7758-7775.	1.5	26
24	Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased Dependency on Scavenger Receptor Class B Type I and Low-Density Lipoprotein Receptor for Hepatitis C Virus. Journal of Virology, 2014, 88, 1725-1739.	1.5	43
25	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1–6. Virology, 2014, 458-459, 190-208.	1.1	20
26	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology, 2013, 58, 1587-1597.	3.6	47
27	Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein. Journal of Virology, 2013, 87, 37-51.	1.5	109
28	Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1–7 in Infectious Cell Culture Systems. PLoS Pathogens, 2012, 8, e1002696.	2.1	34
29	Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate. PLoS Pathogens, 2012, 8, e1002653.	2.1	201
30	Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography. Virology, 2011, 409, 148-155.	1.1	22
31	Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization. Journal of Virology, 2011, 85, 2224-2234.	1.5	128
32	Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step. Journal of Virology, 2011, 85, 7005-7019.	1.5	120